TOV-112D cells
USD$550.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | TOV-112D is a human endometrioid ovarian carcinoma cell line established from the primary ovarian tumor of a 42-year-old Caucasian female patient. The line grows as an adherent monolayer. TOV-112D harbors a TP53 p.Ser37Ala (homozygous) substitution in the transactivation domain, a homozygous PTEN frameshift mutation (p.Leu639fs), and a TP53 p.Arg175His mutation. This combination of TP53 and PTEN alterations makes TOV-112D a relevant model for studying endometrioid-type ovarian carcinoma, which frequently harbors concurrent TP53, PTEN, and CTNNB1 mutations. The doubling time is approximately 22–29 hours. TOV-112D is applicable in studies of endometrioid ovarian carcinoma biology, TP53 mutant phenotype, PTEN loss and PI3K/Akt pathway activation, drug sensitivity evaluation (carboplatin, paclitaxel, PARP inhibitors), and gynecological oncology research. It is suitable for in vitro pharmacological assays and xenograft models in immunocompromised hosts for preclinical ovarian cancer drug evaluation. |
|---|---|
| Organism | Homo sapiens (Human) |
| Tissue | Ovary |
| Disease | Endometrioid carcinoma of ovary |
| Metastatic site | Primary tumor site (ovary) |
| Applications | Endometrioid ovarian carcinoma; TP53 mutant tumor biology; PTEN loss and PI3K/Akt activation; drug sensitivity (carboplatin, paclitaxel, PARP inhibitors); gynecological oncology; xenograft models |
| Synonyms | TOV-112d, TOV112D, TOV-112, TOV112 |
Characteristics
| Age | 42Y |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Epithelial-like |
| Cell type | Epithelial cells |
| Growth properties | Adherent |
Regulatory Data
| Citation | TOV-112D (Cytion catalog number 305584) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_3612 |
| GMO Status | No genetic modification; wildtype ovarian carcinoma cell line with somatic TP53 and PTEN mutations |
Biomolecular Data
| Mutational profile | Mutation: p.Ser37Ala, Homozygous; Mutation: p.Leu639fs, Homozygous; Mutation: p.Arg175His, Unspecified |
|---|
Handling
| Culture Medium | The base medium for this cell line is a 1:1 mixture of MCDB 105 medium containing a final concentration of 1.5 g/L sodium bicarbonate and Medium 199 containing a final concentration of 2.2 g/L sodium bicarbonate |
|---|---|
| Supplements | Supplement the medium with 15% FBS |
| Dissociation Reagent | Accutase |
| Doubling time | 0.8 day ; 1.0 +- 0.2 days ; 22 hours ; 1.49 days ; 29.13 hours |
| Subculturing | Remove medium, wash with PBS without calcium and magnesium, cover with Accutase, incubate 8–10 min at RT, resuspend in medium, centrifuge 300×g 3 min, discard supernatant, reseed in fresh medium. |
| Split ratio | 1 to 5 |
| Seeding density | 2-4*10^4/cm² |
| Fluid renewal | Every 2 to 3 days |
| Freeze medium | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |